State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer

Frontiers in Oncology

Oncology

Sen Lian¹  Young Do Jung²  Shreesh Ojha³  Abdulqadir Ismail M. Abdullah Alzarooni⁴  Ajeet Kaushik⁵  Mohamed Yazeer Ameer⁶  Saravanan Ramesh⁶  Preethi Selvakumar⁶  Vinoth-Kumar Lakshmanan⁷  Salem Chouaib⁸  Ashutosh Tiwari⁹  Anshuman Mishra⁹ 

[1] Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China;Department of Biochemistry, Chonnam National University Medical School, Gwangju, Republic of Korea;Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates;Department of Urology, H.H. Sheikh Khalifa General Hospital, Al Salama, Opp. Ministry of Community Development, Umm Al Quwain, United Arab Emirates;NanoBioTech Laboratory, Department of Environmental Engineering, Florida Polytechnic University, Lakeland, FL, United States;School of Engineering, University of Petroleum and Energy Studies (UPES), Dehradun, India;Prostate Cancer Biomarker Laboratory, Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research, Chennai, India;Prostate Cancer Biomarker Laboratory, Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research, Chennai, India;Translational Research & Sustainable Healthcare Management, Institute of Advanced Materials, IAAM, Ulrika, Sweden;Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman, United Arab Emirates;INSERM UMR1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, Equipe Labellisée par la Ligue Contre le Cancer, EPHE, Faculté de Médecine, Université Paris-Sud, Université Paris-Saclay, Villejuif, France;Translational Research & Sustainable Healthcare Management, Institute of Advanced Materials, IAAM, Ulrika, Sweden;

关键词: prostate cancer;    cancer stem cells;    immunotherapy;    chemotherapy;    CRISPR;    nanotechnology;    photothermal ablation therapy;   

DOI  :  10.3389/fonc.2023.1059441

 received in 2022-10-01, accepted in 2023-01-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

The development of new therapeutic strategies is on the increase for prostate cancer stem cells, owing to current standardized therapies for prostate cancer, including chemotherapy, androgen deprivation therapy (ADT), radiotherapy, and surgery, often failing because of tumor relapse ability. Ultimately, tumor relapse develops into advanced castration-resistant prostate cancer (CRPC), which becomes an irreversible and systemic disease. Hence, early identification of the intracellular components and molecular networks that promote prostate cancer is crucial for disease management and therapeutic intervention. One of the potential therapeutic methods for aggressive prostate cancer is to target prostate cancer stem cells (PCSCs), which appear to be a primary focal point of cancer metastasis and recurrence and are resistant to standardized therapies. PCSCs have also been documented to play a major role in regulating tumorigenesis, sphere formation, and the metastasis ability of prostate cancer with their stemness features. Therefore, the current review highlights the origin and identification of PCSCs and their role in anti-androgen resistance, as well as stemness-related signaling pathways. In addition, the review focuses on the current advanced therapeutic strategies for targeting PCSCs that are helping to prevent prostate cancer initiation and progression, such as microRNAs (miRNAs), nanotechnology, chemotherapy, immunotherapy, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene-editing system, and photothermal ablation (PTA) therapy.

【 授权许可】

Unknown   
Copyright © 2023 Ramesh, Selvakumar, Ameer, Lian, Abdullah Alzarooni, Ojha, Mishra, Tiwari, Kaushik, Jung, Chouaib and Lakshmanan